Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough
admin 18th July 2018 Uncategorised 0Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough designation from the FDA in previously untreated liver cancer patients, putting it on a path to speedy approval.
More: Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough
Source: fierce